Global In Vitro Diagnostics Market
In vitro diagnostics market: Invitro diagnostics are used to detect infectious diseases, and also used to monitor the health status of a person and therapeutic procedures by examining the specimens like blood, tissue, urine, stools and other bodily fluids. Various technologies are incorporated in in-vitro diagnostics such as microarray techniques, mass spectrometry, polymerase chain reaction and sequencing technology are used for testing the sample preparation.
Increasing expenditure on healthcare sector in emerging markets, huge demand for novel diagnostic methods for diagnosis of the diseases are expected to create demand for in vitro diagnostics. Rising adaptation of point care testing, rising incidences of lifestyle diseases are expected to boost the market. As per 2014 report of National Diabetes Statistics states that about 9.3% of U.S. population have diabetes and about 8.1 Mn people are undiagnosed, In accordance with WHO, about 5 Mn deaths were recorded because of the chronic diseases like TB, Malaria, and AIDS in 2011, around 8.7 Mn cases registered due to TB. Cancer accounted for 7.9 Mn deaths and anticipated to reach 11 Mn by 2030. Increase in the number of laboratories with sophisticated infrastructure in developed countries is the few factors expected to boost the growth of In vitro diagnostics market. However, unfavourable reimbursement policies in developing countries and strict regulatory framework are few factors that are restraining the growth of the IVD market.
The In Vitro Diagnostics (IVD) market is classified on the basis of product type, application, techniques, end user and geography.
Based on product type, In vitro diagnostics market is segmented into the following
- Reagents and consumables
Based on techniques, In vitro diagnostics market is segmented into the following
- Molecular diagnostics
- Clinical chemistry
- Tissue diagnostics
- Hemostasis and Coagulation
Based on Application, In vitro diagnostics (IVD) market is segmented into the following
- Infectious diseases
- Nephrological diseases
- Immune system disorders
- Gastrointestinal disorders
- Neurological disorders
- Hematological disorders
Based on end user, In vitro diagnostics market is segmented into the following
- Diagnostic Centres
- Point-of-care testing
Players in In vitro diagnostics are focusing on acquisitions, exclusive agreements and strategic collaborations in order to expand their business. In February 2015, Roche has acquired Signature Diagnostics to strengthen its cancer diagnostics. In February 2014, Thermo Fisher Scientific has acquired Life Technologies Corporation to strengthen it’s of next-generation sequencing space segment. Different organizations are being operated in order to monitor the industry. For example, BIVDA (British In Vitro Diagnostics Association) is an association of various companies in the UK which represents the manufacturers and distributors with high interest and involvement. Recently, Life Technology Corporation in Europe has launched CE-IVD Marked QuantStudio Dx Real-Time PCR instrument.
On the basis of geographical regions, is In vitro diagnostics market classified as into five key regions as Europe, Asia- Pacific, North America, Europe, Middle East & Africa and Latin America. North America is the largest market with the highest share of the IVD market, which is followed by the Europe owing easy accessibility for advanced technologies, the presence of the large pool of manufacturers in IVD market, increasing the prevalence of chronic genetic and lifestyle diseases. Asia-Pacific is expected to show fastest growth rate and also will emerge as the area with maximum growth potential owing to the improving infrastructure of the healthcare sector and growing economies in India and China.
The key players in this market are Becton, Dickinson and Company (U.S.), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (U.S.), Sysmex Corporation (Japan), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Qiagen N.V. (Germany), Diasorin S.P.A. (Italy).Ortho-Clinical Diagnostics, Inc. (U.S.), and Johnson and Johnson (U.S.).
- In 2015 April, Abbott and Sekisui entered into an agreement for providing solutions of coagulation testing for laboratories across the world.
- In 2014 December, Roche expanded its CE-IVD for testing of human organ and tissue for next-gen blood screening assays. cobas MPX and Cobas WNV assays can be used to test tissue and human organ, therefore expanding the range of approved uses for the cobas 6800/8800 systems and assays.
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario